MedTech News
.................... by Andrew Celentano

Hyperice Unveils Normatec Elite Heat Legs for Enhanced Muscle Recovery
The combination of both heat and compression drives the therapeutic benefits deeper into the legs for a more amplified experience

Scientists identify inhibition of a specific enzyme as a promising target to treat pancreatic cancer
Researchers have identified a promising new target in the treatment of pancreatic cancer.

New surface coating could help implants bond better with bone in people with diabetes
Flinders University researchers are launching an innovative surface-engineering technology that could help to raise the performance of implantable medical devices in people with diabetes and other metabolic diseases.

Magnetic fields can revive intracellular transport in ALS
A study led by cell biologist Dr. Arun Pal at the HZDR, in collaboration with research partners in Dresden and Rostock, has found that electromagnetic alternating fields can partially reverse key pathological changes in human nerve cells

Portable test detects Zika and hepatitis C in hours without lab-grade equipment
A new protocol detects RNA viruses such as Zika and hepatitis C without traditional medical laboratory equipment.

FDA-approved drug kills cancer cells in lab by disrupting cellular recycling
Researchers from VCU Massey Comprehensive Cancer Center recently demonstrated that the inhibition of glucosylceramide synthase (GCS) can cause death in cancer cells that is independent of changes in pro-death ceramide levels.

Scientists turn protein-making errors in cancer cells into a targeted kill switch
A recent Nature study investigated whether a protein-building glitch in cancer cells can be turned into a targeted cancer therapy.

Beckman Coulter Diagnostics Receives U.S. FDA Clearance for Rapid Bacterial vs. Viral Assay Providing Results in as Little as 15 Minutes for Adults and Children
BREA, Calif., Nov. 3, 2026 /PRNewswire/ — Beckman Coulter Diagnostics, a Danaher company and a global leader in clinical diagnostics, today announced U.S. FDA clearance of the Access MeMed BV® assay, a rapid host-response blood test that helps clinicians distinguish bacterial from viral infections in adult and pediatric patients. Available on the DxI 9000 and Access 2 immunoassay analyzers already installed in hospital laboratories nationwide, the new assay provides timely information aiding treatment decisions without requiring new instrumentation or changes to existing testing workflows. On the DxI 9000 Analyzer, results are available in as little as 15 minutes.